Immuno-Oncology
We are focused on advancing a diversified portfolio of next-generation immuno-oncology therapies to transform cancer treatment and extend survival for patients with hard-to-treat tumors.
Anti-PD-1 Monoclonal Antibody
LOQTORZI® (toripalimab-tpzi) is the only available FDA-approved therapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) in combination with chemotherapy or as a single agent.
Our Programs
View Our Pipeline
Developing a Portfolio of Immuno-Oncology Drugs to Improve Patient Outcomes
Our pipeline includes multiple clinical stage immuno-oncology drug candidates that target the tumor microenvironment.
Our Clinical Trials
See Clinical Trials
Testing the Safety and Effectiveness of Our I-O Drug Candidates
We have multiple ongoing clinical trials across a range of cancer indications assessing our investigational immuno-oncology therapeutics.
Become part of our talented and passionate organization and make an impact.
